Product Description
Anti-CD3/CD19/CD20 Trispecific Antibody. (Sourced from: https://www.cancer.gov/research/participate/clinical-trials/intervention/anti-cd3-cd19-cd20-trispecific-antibody-1a46?redirect=true?redirect=true)
Mechanisms of Action: CD20 Inhibitor, CD19 Inhibitor, CD3 Inhibitor
Novel Mechanism: No
Modality: Trispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: Chimagen Biosciences
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia
Phase 1: Acute Respiratory Distress Syndrome|T-Cell Lymphoma|Lymphoma, B-Cell|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2300075049 |
ChiCTR2300075049 | N/A |
Not yet recruiting |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell |
2030-04-30 |
2023-08-24 |
Treatments |
|
CTR20232077 |
CTR20232077 | N/A |
Terminated |
T-Cell Lymphoma|Lymphoma, B-Cell|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
NCT05987605 |
B - NHL | P1 |
Terminated |
T-Cell Lymphoma|Lymphoma, B-Cell|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin|Acute Respiratory Distress Syndrome |
2024-08-20 |
2025-02-20 |
Primary Completion Date|Primary Endpoints |
|
NCT05348889 |
CMG1A46-US01 | P2 |
Terminated |
Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2024-10-31 |
2025-02-14 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|